Onglyza saxagliptin regulatory update

Otsuka and Kyowa Hakko Kirin said Japan approved Onglyza saxagliptin to treat Type II diabetes. Kyowa has exclusive, Japanese rights to develop and commercialize saxagliptin under a June 2012 deal (se...